Aug. 5 at 12:30 AM
$CANF The discovery of Piclidenoson’s potential effect in Lowe syndrome emerged from a high-throughput screening of over 1,300 compounds conducted by De Matteis’ team. Through deep investigation into the mechanisms of cellular trafficking—one of her areas of global expertise—they identified a precise molecular target that plays a key role in the progressive kidney damage caused by the disease. Validation in both cell and animal models confirmed that Piclidenoson could restore critical renal functions.
